Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC
Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />
Martin H. Voss, MD, medical oncologists, Memorial Sloan Kettering Cancer Center, reviews the method of design and results for the phase I/II study of the experimental antiPD-1 anitbody MEDI0680 plus durvalumab (Imfinzi) versus nivolumab (Opdivo) monotherapy in patients with metastatic clear cell renal cell carcinoma (ccRCC) (NCT02118337).
The study was a randomized, open-label study evaluating the safety, efficacy, and the anti-tumor activity of the MEDI0680/durvalumab combination. The research hypothesis behind the evaluation was that monotherapy alone would not have an effect on all of the interactions between the cells and continue to inhibit the tumor microenvironment. Combinations of PD-1 and PD-L1 agents, on the other hand, can block the interactions between cells.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
